vs
Side-by-side financial comparison of BRUNSWICK CORP (BC) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.3B, roughly 1.8× BRUNSWICK CORP). Zoetis runs the higher net margin — 25.3% vs 1.4%, a 23.9% gap on every dollar of revenue. On growth, BRUNSWICK CORP posted the faster year-over-year revenue change (15.5% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $83.6M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -1.1%).
Brunswick Corporation, formerly known as the Brunswick-Balke-Collender Company, is an American corporation that has been developing, manufacturing and marketing a wide variety of products since 1845. Brunswick has more than 13,000 employees in 24 countries. Brunswick owns a number of brands, including Mercury Marine. In 2024, Brunswick reported sales of US$5.2 billion. Brunswick's global headquarters is in the northern Chicago suburb of Mettawa, Illinois.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
BC vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.4B |
| Net Profit | $18.7M | $603.0M |
| Gross Margin | 23.1% | 70.2% |
| Operating Margin | 3.1% | 31.9% |
| Net Margin | 1.4% | 25.3% |
| Revenue YoY | 15.5% | 3.0% |
| Net Profit YoY | 122.7% | 3.8% |
| EPS (diluted) | $0.32 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.4B | $2.5B | ||
| Q1 25 | $1.2B | $2.2B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $1.4B | $2.4B | ||
| Q1 24 | $1.4B | $2.2B |
| Q4 25 | $18.7M | $603.0M | ||
| Q3 25 | $-235.5M | $721.0M | ||
| Q2 25 | $59.3M | $718.0M | ||
| Q1 25 | $20.2M | $631.0M | ||
| Q4 24 | $-82.5M | $581.0M | ||
| Q3 24 | $44.6M | $682.0M | ||
| Q2 24 | $100.0M | $624.0M | ||
| Q1 24 | $68.0M | $599.0M |
| Q4 25 | 23.1% | 70.2% | ||
| Q3 25 | 25.8% | 71.5% | ||
| Q2 25 | 25.5% | 73.6% | ||
| Q1 25 | 24.9% | 72.0% | ||
| Q4 24 | 21.9% | 69.5% | ||
| Q3 24 | 26.2% | 70.6% | ||
| Q2 24 | 27.1% | 71.7% | ||
| Q1 24 | 27.4% | 70.6% |
| Q4 25 | 3.1% | 31.9% | ||
| Q3 25 | -17.8% | 37.0% | ||
| Q2 25 | 7.1% | 36.7% | ||
| Q1 25 | 4.6% | 36.5% | ||
| Q4 24 | -4.8% | 31.6% | ||
| Q3 24 | 7.7% | 36.6% | ||
| Q2 24 | 11.0% | 33.0% | ||
| Q1 24 | 8.1% | 34.1% |
| Q4 25 | 1.4% | 25.3% | ||
| Q3 25 | -17.3% | 30.0% | ||
| Q2 25 | 4.1% | 29.2% | ||
| Q1 25 | 1.7% | 28.4% | ||
| Q4 24 | -7.1% | 25.1% | ||
| Q3 24 | 3.5% | 28.6% | ||
| Q2 24 | 6.9% | 26.4% | ||
| Q1 24 | 5.0% | 27.4% |
| Q4 25 | $0.32 | $1.37 | ||
| Q3 25 | $-3.59 | $1.63 | ||
| Q2 25 | $0.89 | $1.61 | ||
| Q1 25 | $0.30 | $1.41 | ||
| Q4 24 | $-1.21 | $1.29 | ||
| Q3 24 | $0.67 | $1.50 | ||
| Q2 24 | $1.48 | $1.37 | ||
| Q1 24 | $0.99 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $256.8M | — |
| Total DebtLower is stronger | $2.1B | — |
| Stockholders' EquityBook value | $1.6B | $3.3B |
| Total Assets | $5.3B | $15.5B |
| Debt / EquityLower = less leverage | 1.30× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $256.8M | — | ||
| Q3 25 | $297.7M | $2.1B | ||
| Q2 25 | $315.7M | $1.4B | ||
| Q1 25 | $286.7M | $1.7B | ||
| Q4 24 | $269.0M | $2.0B | ||
| Q3 24 | $284.1M | $1.7B | ||
| Q2 24 | $494.5M | $1.6B | ||
| Q1 24 | $548.4M | $2.0B |
| Q4 25 | $2.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.6B | $3.3B | ||
| Q3 25 | $1.6B | $5.4B | ||
| Q2 25 | $1.9B | $5.0B | ||
| Q1 25 | $1.9B | $4.7B | ||
| Q4 24 | $1.9B | $4.8B | ||
| Q3 24 | $2.0B | $5.2B | ||
| Q2 24 | $2.0B | $5.0B | ||
| Q1 24 | $2.0B | $5.1B |
| Q4 25 | $5.3B | $15.5B | ||
| Q3 25 | $5.4B | $15.2B | ||
| Q2 25 | $5.8B | $14.5B | ||
| Q1 25 | $5.9B | $14.1B | ||
| Q4 24 | $5.7B | $14.2B | ||
| Q3 24 | $6.0B | $14.4B | ||
| Q2 24 | $6.4B | $14.2B | ||
| Q1 24 | $6.5B | $14.3B |
| Q4 25 | 1.30× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $132.9M | $893.0M |
| Free Cash FlowOCF − Capex | $83.6M | $732.0M |
| FCF MarginFCF / Revenue | 6.3% | 30.7% |
| Capex IntensityCapex / Revenue | 3.7% | 6.7% |
| Cash ConversionOCF / Net Profit | 7.11× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $396.3M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $132.9M | $893.0M | ||
| Q3 25 | $140.4M | $938.0M | ||
| Q2 25 | $316.2M | $486.0M | ||
| Q1 25 | $-27.4M | $587.0M | ||
| Q4 24 | $306.4M | $905.0M | ||
| Q3 24 | $67.4M | $951.0M | ||
| Q2 24 | $211.0M | $502.0M | ||
| Q1 24 | $-153.4M | $595.0M |
| Q4 25 | $83.6M | $732.0M | ||
| Q3 25 | $106.5M | $805.0M | ||
| Q2 25 | $271.3M | $308.0M | ||
| Q1 25 | $-65.1M | $438.0M | ||
| Q4 24 | $276.1M | $689.0M | ||
| Q3 24 | $31.4M | $784.0M | ||
| Q2 24 | $163.9M | $370.0M | ||
| Q1 24 | $-207.4M | $455.0M |
| Q4 25 | 6.3% | 30.7% | ||
| Q3 25 | 7.8% | 33.5% | ||
| Q2 25 | 18.7% | 12.5% | ||
| Q1 25 | -5.3% | 19.7% | ||
| Q4 24 | 23.9% | 29.7% | ||
| Q3 24 | 2.5% | 32.8% | ||
| Q2 24 | 11.4% | 15.7% | ||
| Q1 24 | -15.2% | 20.8% |
| Q4 25 | 3.7% | 6.7% | ||
| Q3 25 | 2.5% | 5.5% | ||
| Q2 25 | 3.1% | 7.2% | ||
| Q1 25 | 3.1% | 6.7% | ||
| Q4 24 | 2.6% | 9.3% | ||
| Q3 24 | 2.8% | 7.0% | ||
| Q2 24 | 3.3% | 5.6% | ||
| Q1 24 | 4.0% | 6.4% |
| Q4 25 | 7.11× | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | 5.33× | 0.68× | ||
| Q1 25 | -1.36× | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 1.51× | 1.39× | ||
| Q2 24 | 2.11× | 0.80× | ||
| Q1 24 | -2.26× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BC
| Engine Partsand Accessories | $532.4M | 40% |
| Navico Group | $452.9M | 34% |
| Recreational Fiberglass Boats | $111.6M | 8% |
| Saltwater Fishing Boats | $85.7M | 6% |
| Controls Riggingand Propellers | $78.3M | 6% |
| Business Acceleration | $48.1M | 4% |
| Sterndrive Engine | $32.6M | 2% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
